Bristol Myers Squibb (BMY) Acquisitions (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Acquisitions for 16 consecutive years, with $91.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Acquisitions fell 68.07% year-over-year to $91.0 million in Q2 2026; TTM through Jun 2026 was $3.7 billion, a 393.01% increase from a year earlier, with the FY2025 full-year figure at $3.9 billion, down 81.93% from the prior year.
• Acquisitions was $91.0 million for Q2 2026 at Bristol Myers Squibb, up from $65.0 million in the prior quarter.
• Over five years, Acquisitions peaked at $20.1 billion in Q1 2024 and troughed at $47.0 million in Q4 2024.
• A 5-year average of $1.7 billion and a median of $337.0 million in 2023 frame the typical range for Acquisitions.
• Across the five-year window, Acquisitions soared 25608.97% in 2024 and tumbled 99.61% in 2025, its largest moves.
• Over 5 years, Acquisitions stood at $116.0 million in 2022, then soared by 400.86% to $581.0 million in 2023, then sank by 91.91% to $47.0 million in 2024, then soared by 3531.91% to $1.7 billion in 2025, then slumped by 94.67% to $91.0 million in 2026.
• The last three Acquisitions figures came in at $91.0 million (Q2 2026), $65.0 million (Q1 2026), and $1.7 billion (Q4 2025), per Business Quant data.